(R)-2-氨基-3-苄氧基-1-丙醇盐酸盐 | 58577-95-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-2-氨基-3-苄氧基-1-丙醇盐酸盐
• 中文别名: (R)-2-氨基-3-(苄氧基)丙烷-1-醇盐酸盐
• 英文名称: (2R)-2-amino-3-(benzyloxy)propan-1-ol hydrochloride
• 英文别名: (2R)-2-amino-3-benzyloxypropanol hydrochloride；(R)-2-amino-3-(benzyloxy)propan-1-ol hydrochloride；(2R)-2-amino-3-phenylmethoxypropan-1-ol;hydrochloride
• CAS: 58577-95-0
• 化学式: C₁₀H₁₅NO₂*ClH
• 分子量: 217.696
• InChiKey: BJWHQBTUHVIRJJ-HNCPQSOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.94
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体环境中。

反应信息

• 作为反应物：
  描述：

  (R)-2-氨基-3-苄氧基-1-丙醇盐酸盐 在 sodium tetrahydroborate 、 potassium tert-butylate 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 S-(2-{(4S)-4-[(benzyloxy)methyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl) ethanethioate
  参考文献：
  名称：

  Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

  摘要：

  To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified gamma-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the gamma-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.009
• 作为产物：
  描述：

  N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 以79%的产率得到(R)-2-氨基-3-苄氧基-1-丙醇盐酸盐
  参考文献：
  名称：

  Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

  摘要：

  To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified gamma-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the gamma-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.009

文献信息

• 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Tani Kousuke

  公开号：US20050124577A1

  公开（公告）日：2005-06-09

  An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal cell death, dysmenorrhea, premature birth, abortion, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, liver cirrhosis, shock, nephritis, renal failure, circulatory diseases, systemic inflammatory response syndrome, sepsis, hemophagocytosis syndrome, macrophage activation syndrome, still disease, Kawasaki Disease, burn, systemic granuloma, ulcerative colitis, Crohn disease, hypercytokinemia at dialysis, multiple organ failure, or bone diseases etc.

  一种由式(I)所表示的8-氮杂前列腺素，其中所有符号的含义与说明书中描述的相同，其药学上可接受的盐或环糊精包合物。由于式(I)所表示的化合物强烈结合到PGE受体中的EP2亚型，因此它对于预防和/或治疗免疫性疾病、过敏性疾病、神经元细胞死亡、痛经、早产、流产、脱发、青光眼等视网膜神经病变、勃起功能障碍、关节炎、肺损伤、肺纤维化、肺气肿、支气管炎、慢性阻塞性肺疾病、肝损伤、急性肝炎、肝硬化、休克、肾炎、肾功能衰竭、循环系统疾病、全身性炎症反应综合征、脓毒症、吞噬细胞过多综合征、巨噬细胞激活综合征、斯蒂尔病、川崎病、烧伤、全身性肉芽肿、溃疡性结肠炎、克隆氏病、透析时的高细胞因子血症、多器官衰竭或骨疾病等方面具有用途。
• Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds
  申请人：Griesgraber W. George

  公开号：US20080085895A1

  公开（公告）日：2008-04-10

  Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R 1 )— group in the fused ring at the 1-position of the imidazo ring, wherein R 1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及一种替代融合[1,2]咪唑[4,5-c]环化合物（例如咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其中在咪唑环的1位的融合环中包含—CH（—R1）—基团，其中R1包括一个官能团，例如酰胺，磺酰胺，脲，氨基甲酸酯，酯，酮，醚，上述的硫代物，磺酰，肟或羟胺，以及包含这些化合物的制药组合物，中间体，制备这些化合物的方法以及这些化合物作为免疫调节剂的用途，用于诱导动物细胞因子生物合成和治疗包括病毒和肿瘤疾病的方法。
• 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT
  申请人：TANI Kousuke

  公开号：US20090042885A1

  公开（公告）日：2009-02-12

  An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal cell death, dysmenorrhea, premature birth, abortion, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, liver cirrhosis, shock, nephritis, renal failure, circulatory diseases, systemic inflammatory response syndrome, sepsis, hemophagocytosis syndrome, macrophage activation syndrome, still disease, Kawasaki Disease, burn, systemic granuloma, ulcerative colitis, Crohn disease, hypercytokinemia at dialysis, multiple organ failure, or bone diseases etc.

  式（I）所表示的8-氮代前列腺素化合物（其中所有符号的含义与说明书中描述的相同），其药学上可接受的盐或环糊精包合物。由于式（I）所表示的化合物强烈结合到PGE受体中的EP2亚型，因此它对预防和/或治疗免疫性疾病、过敏性疾病、神经元细胞死亡、痛经、早产、流产、脱发、青光眼等视网膜神经病变、勃起功能障碍、关节炎、肺损伤、肺纤维化、肺气肿、支气管炎、慢性阻塞性肺疾病、肝损伤、急性肝炎、肝硬化、休克、肾炎、肾衰竭、循环系统疾病、全身炎症反应综合征、败血症、吞噬细胞综合征、巨噬细胞活化综合征、斯蒂尔病、川崎病、烧伤、全身性肉芽肿、溃疡性结肠炎、克罗恩病、透析时的高细胞因子血症、多器官功能障碍或骨疾病等方面具有用处。
• SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
  申请人：Griesgraber George W.

  公开号：US20110293654A1

  公开（公告）日：2011-12-01

  Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R 1 )— group in the fused ring at the 1-position of the imidazo ring, wherein R 1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及具有融合的[1,2]咪唑[4,5-c]环化合物（例如，咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其在咪唑环的1位处具有一个—CH（—R1）—基团，其中R1包括一个功能基团，例如酰胺，磺酰胺，脲，氨基甲酸酯，酯，酮，醚，上述的硫代物，磺酰，肟或羟胺，以及包含该化合物的制药组合物，中间体，制备该化合物的方法以及将这些化合物用作免疫调节剂的方法，用于诱导动物细胞因子生物合成并治疗包括病毒和肿瘤疾病在内的疾病。
• Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
  申请人：3M Innovative Properties Company

  公开号：US08034938B2

  公开（公告）日：2011-10-11

  Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及替代的融合[1,2]咪唑[4,5-c]环化合物（例如咪唑[4,5-c]喹啉，6,7,8,9-四氢咪唑[4,5-c]喹啉，咪唑[4,5-c]萘啉和6,7,8,9-四氢咪唑[4,5-c]萘啉），其中在咪唑环的1位的融合环中包括一个—CH(—R1)—基团，其中R1包括一个官能团，例如酰胺，磺酰胺，脲，氨基甲酸酯，酯，酮，醚，上述物质的硫代物，砜，肟或羟肟，以及包含这些化合物的药物组合物，中间体，制备这些化合物的方法以及这些化合物作为免疫调节剂的用途，用于诱导动物的细胞因子生物合成和治疗包括病毒和肿瘤疾病的疾病。